DexCom, Inc. (DXCM) Earnings Call Transcripts

DexCom, Inc.'s Latest Earnings Call - Q2 FY2026

In the second quarter of 2026, DexCom, Inc. reported revenue of $1.31 billion, reflecting a 13% increase year-over-year, driven by strong demand for its continuous glucose monitoring (CGM) systems. The company raised its full-year revenue guidance to a range of $5.18 billion to $5.25 billion, indicating growth of 11% to 13%. Adjusted EBITDA margin guidance was also increased to a range of 31.5% to 32%, showcasing improved operational efficiency and strong product performance.

Reported metrics

Guidance from management

DexCom raised its full-year revenue guidance to $5.18 billion to $5.25 billion, reflecting growth of 11% to 13%. The company also increased its gross profit margin guidance to approximately 64%.

What management said

Thank you, Jereme. As a reminder, we ask our audience to limit themselves to only one question at this time and then reenter the queue if necessary. Operator, please provide the Q&A instructions.

Yes. We did submit the CONNECT data to CMS. And again, it adds to that pretty substantial body of evidence that was already there. No change in our assumptions around the coverage decision. We do expect to hear back from CMS on that decision before the end of this year. And in our plans right now, we've got it taking effect in the middle of 2027. That being said, I do believe that CONNECT is a pretty powerful data se...

What analysts pressed on

Analysts expressed concerns about the sustainability of CGM growth in the U.S. market, particularly regarding the potential impact of upcoming Medicare coverage decisions. There were also questions about the integration and revenue contribution from the Nutrisense acquisition.

Main topics on the call

• Strong Revenue Growth — DexCom achieved second quarter revenue of $1.31 billion, up 13% from $1.16 billion in Q2 2025. Management noted, "We carried forward solid demand from the first quarter for Dexcom CGM globally as we benefited from broade...
• CONNECT Trial Results — The CONNECT trial for type 2 diabetes patients showed a 1.6% A1c improvement for the CGM group, with a 97% median usage rate. Leach stated, "These results are even better than what we saw in our landmark DIAMOND and MOBI...
• Increased Guidance — DexCom raised its revenue guidance for the year to $5.18 billion to $5.25 billion, reflecting stronger organic growth expectations. Sylvain mentioned, "This updated revenue guidance reflects stronger organic growth expec...
• International Market Expansion — International revenue grew 19% to $375 million, with strong performances in newly accessible markets like France and Canada. Sylvain noted, "Some of our strongest performances came from markets where access has recently ...

Read the full DexCom, Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 74 DexCom, Inc. earnings call transcripts on record, spanning January 13, 2020 to July 30, 2026. Based on this history, DexCom, Inc. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

DXCM

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

74

First call

January 13, 2020

Most recent

July 30, 2026

Reporting cadence

quarterly